Psychotropic drug-induced change of weight: A review;Gewichtsveränderungen unter therapie mit psychopharmaka

Fortschritte der Neurologie Psychiatrie

Volumn 75, Issue 2, 2007, Pages 65-80

  Drieling, T ^a   Biedermann, N C ^a   Scharer L O ^a   Strobl, N ^a   Langosch, Jens M ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ARIPIPRAZOLE; CARBAMAZEPINE; CITALOPRAM; CLOZAPINE; FELBAMATE; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; IMIPRAMINE; LAMOTRIGINE; LITHIUM; MAPROTILINE; MIRTAZAPINE; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; PHENELZINE; PIMOZIDE; QUETIAPINE; RISPERIDONE; SERTRALINE; TOPIRAMATE; TRAZODONE; UNINDEXED DRUG; VALPROIC ACID; VIGABATRIN; ZIPRASIDONE;

CLINICAL RESEARCH; HUMAN; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; WEIGHT; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION;

ANIMALS; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANTIPSYCHOTIC AGENTS; HUMANS; PSYCHOTROPIC DRUGS; SEROTONIN UPTAKE INHIBITORS; WEIGHT GAIN;

EID: 34247176615     PISSN: 07204299     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-919109     Document Type: Review

References (219)

1. Gordon HL, Law A, Hohman KE. The problem of overweight in hospitalized psychotic patients. Psychiatry Q 1969; 34: 69-82
2. Gopalaswamy AK, Morgan R. Too many chronic mentally disabled patients are too fat. Acta Psychiatr Scand 1985; 72: 254-258
3. Bernstein JG. Psychotropic drug induced weight gain: Mechanisms and management. Clin Neuropharmacology 1988; 11: 194-206
4. Brady KT. Weight gain associated with psychotropic drugs. South Med J 1989; 82: 611-617
5. Kannel WB. Fifty years of Framingham Study contributions to understanding hypertension. J Hum Hypertension 2000; 14: 83-90
6. Manson JE, Willett WC, Stampfer MJ. Body weight and mortality among women. N Eng J Med 1995; 333: 677-685
7. Garfinkel L. Overweight and cancer. Ann Intern Med 1985; 103: 1034-1036
8. Stampfer MJ, Maclure KM, Colditz GA. Risk of symptomatic gallstones in women with severe obesity. Ann J Clin Nutr 1992; 71 (suppl.): 1242-1248
9. Sturmer T, Gunther KP, Brenner H. Obesity, overweight and patterns of osteoarthritis: the Ulm Osteoarthritis Study. J Clin Epidemiol 2000; 53: 307-313
10. Guilleminault C, Quera-Salva MA, Partinen M. Women and the obstructive sleep apnea syndrome. Chest 1988; 93: 104-109
11. Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995; 122: 481-486
12. Wolf AM, Colditz GA. Current estimates of the economic costs of obesity in the United States. Obesity Research 1998; 6: 97-106
13. Samsa GP, Kolotkin RL, Williams GR, Nguyen MH, Mendel CM. Effect of moderate weight loss on health-related quality of life: an analysis of combined data from 4 randomized trials of sibutramine vs placebo. Am J of Managed Care 2001; 7: 926-927
14. Weiden P, Shaw E, Mann J. Causes of neuroleptic compliance. Psychiatr Ann 1986; 16: 571-575
15. Gitlin MJ, Cochran SD, Jamison KR. Maintenance lithium treatment: side effects and compliance. J Clin Psychiatry 1989; 50: 127-131
16. Johnson RE, McFarland BH. Lithium use and discontinuation in a health maintenance organization. Am J Psychiatry 1996; 153: 993-100
17. Mefferd Jr RB, Labrosse EH, Gawienowski AM. Influence of chlorpromazine on certain biochemical variables in chronic male schizophrenics. J Nerv Ment Dis 1958; 127: 167-179
18. Fernstrom MH, Kupfer DJ. Antidepressant-induced weight gain: a comparison study of four medications. Psychiatry Research 1988; 26: 265-271
19. Gendall KA, Joyce PR, Mulder RT, Sullivan PF. The effects of fluoxetine versus nortriptyline on body weight in depression. J Clin Psychopharmacol 2000; 20: 714-715
20. Paradis CF, Stack JA, George CJ, Miller MD, Pollock BG, Rifai AH, Mazumdar S, Perel JM, Reynolds CF. Nortriptyline and weight change in depressed patients over 60. J Clin Psychopharmacol 1992; 12: 246-250
21. Weber E, Stack J, Pollock BG, Mulsant B, Begley A, Mazumdar S, Reynolds CF. Weight change in older depressed patients during acute pharmacotherapy with paroxetine and nortriptyline: a double-blind randomized trial. American Journal of Geriatric Psychiatry 2000; 8: 245-250
22. Aberg-Wistedt A. A double blind study of zimelidine, a serotonin uptake inhibitor, and desipramine, a noradrenaline uptake inhibitor, in endogenous depression. Clinical findings. Acta Psychiatr Scand 1982; 66: 50-65
23. Stern SL, Cooper TB, Johnson MH. Lack of weight gain under desipramine. Biol Psychiatry 1987; 22: 796-797
24. Levitt AJ, Joffe RT, Esche I. The effect of desipramine on body weight in depression. J Clin Psychiatry 1987; 48: 27-28
25. Sussman N, Ginsberg DL, Bikoff J. Effects of nefazodone on body weight: A pooled analysis of welective serotonin reuptake inhibitor-and imipramine-controlled trials. J Clin Psychiatry 2001; 62: 256-260
26. Frank E, Kupfer DJ, Buhari A, McEachran AB, Grochocinski VJ. Imipramine and weight gain during the long-term treatment of recurrent depression. J Affective Disord 1992; 26: 65-72
27. de Jonghe F, Ravelli DP, Tuynman-Qua H. A randomized, double-blind study of fluoxetine and maprotiline in the treatment of major depression. Pharmacopsychiat 1991; 24: 62-67
28. Robinson D, Corcella J, Feigher JP. A comparison of trazodone, amoxapine, and maprotiline in the treatment of endogenous depression: result of a multicenter study. Curr Ther Res Clin Exp 1984; 35: 449-560
29. Vaz-Serra A, Figueira ML, Firmino H, Albuquerque AJ, Jara JM, Pestana LC. Multicenter double-blind study of moclobemide and maprotiline. Clin Neuropharmacol 1994; 17 (suppl. 1): 38-49
30. Benkert O, Szegedi A, Kohnen R. Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry 2000; 61: 656-663
31. Montgomery SA, Reimitz PE, Zivkov M. Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind placebo-controlled study. Int Clin Psychopharmacol 1998; 13: 63-73
32. Smith WT, Glaudin V, Panagides J, Gilvary E. Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder. Psychopharmacol Bull 1990; 26: 191-196
33. Wade A, Crawford GM, Angus M, Wilson R, Hamilton L. A randomized, double-blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care. Int Clin Psychopharmacol 2003; 18: 133-141
34. Leinonen E, Skarstein J, Behnke K, Agren H, Helsdingen JTh. Efficacy and tolerability of mirtazapine versus citalopram: A double-blind, randomized study in patients with major depressive disorder. Int Clin Psychopharmacol 1999; 14: 329-337
35. Szkudlarek J, Elsborg L. Treatment of severe obesity with highly selective serotonin reuptake inhibitor as a supplement to a low calorie diet. Int J Obes Relat Metab Disord 1993; 17: 681-683
36. Bouwer CD, Harvey BH. Phasic craving for carbohydrate observed with citalopram. Int Clin Psychopharmacol 1996; 11: 273-278
37. Chouinard G, Saxena B, Belanger MC, Ravindran A, Bakish D, Beauclair L, Morris P, Vasavan NN, Manchanda R, Reesal R, Rmick R, O'Neill MC. A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder. J Affect Disord 1999; 54: 39-48
38. Fava M, Judge R, Hoog SL, Nilsson ME, Koke SC. Fluoxetine versus sertraline and paroxetine in major depressive disorder: Changes in weight with long-lerm treatment. J Clin Psychiatry 2000; 61: 863-867
39. Goldstein DJ, Rampey Jr AH, Roback PJ. Efficacy and safety of long-term fluoxetine treatment of obesity - maximising success. Obesity Research 1995; 3: 481-481
40. Michelson D, Amsterdam JD, Qutkin FM, Reimherr FW, Rosenbaum FJ, Zajecka J, Sundell KL, Kim Y, Beasley CM. Changes in weight during a 1-year trial of fluoxetine. Am J Psychiatry 1999; 156: 1170-1176
41. Rudolph RL, Feiger AD. A double-blind, randomized, placebo-controlled trail of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J Affective Disord 1999; 56: 171-181
42. Silverstone T. Moclobemide vs. imipramine in bipolar depression: A multicentre double-blind clinical trial. Acta Psychiatr Scand 2001; 104: 104-109
43. Ferguson J. Fluoxetine-induced weight loss in overweight, nondepressed subjects. Am J Psychiatry 1986; 143: 1496-1496
44. Abell CA, Farquhar DL, Galloway SM, Steven F, Philip AE, Munro JF. Placebo controlled double-blind trial of fluvoxamine maleate in the obese. Journal of Psychosomatic Research 1986; 30: 143-146
45. Davidson J, Yaryura-Tobias J, Dupont R, Stallings L, Barbato L, Hoop R van der, Li D. Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol 2004; 24: 118-125
46. Harris B, Ashford J. Fluvoxamine maintenance therapy is not associated with weight gain. J Psychopharmacol 1990; 4: 299-299
47. Westenberg H, Stein DJ, Yang H, Li D, Barbato L. A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder. J of Clin Psychopharmacol 2004; 24: 49-55
48. Liebowitz MR, Gelenberg AJ, Munjack D. Venlafaxine Extended Release vs Placebo and Paroxetine in Social Anxiety Disorder. Arch Gen Psychiatry 2005; 62: 190-198
49. Silverstone PH, Ravindran A. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. J Clin Psychiatry 1999; 60: 22-28
50. Harrison CL. Ferrier N. Young AH. Tolerability of high-dose venlafaxine in depressed patients. J Psychopharmacol 2004; 18: 200-2004
51. Weihs KL, Settle EC, Batey S, Houser TL, Donahue RMJ, Ascher JA. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. J Clin Psychiatry 2000; 61: 196-202
52. Aberg-Wistedt A, Agren H, Ekselius L, Bengtson F, Akerblad AC. Sertraline versus paroxetine in major depression: clinical outcome after six months of continous therapy. J Clin Psychopharmacol 2000; 20: 645-652
53. Dannon PN, Iancu I, Cohen A, Lowengrub K, Grunhaus L, Kotler M. Three year naturalistic outcome study of panic disorder patients treated with paroxetine. BMC Psychiatry 2004; 4: 16-16
54. Croft H, Settle E, Houser T, Batey SR, Donahue RM, AscherJA. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther 1999; 21: 643-658
55. Feighner J, Hendrickson G, Miller L, Stern W. Double-blind comparison of doxepin versus bupropion in outpatients with a major depressive disorder. J Clin Psychopharmacol 1986; 6: 27-32
56. Weisler RH, Johnston JA, Lineberry CG, Samara B, Branconnier RJ, Billow AA. Comparison of bupropion and trazodone for the treatment of major depression. J Clin Psychopharmacol 1994; 14: 170-179
57. Bakish D, Bradwejn J, Nair N. A comparison of moclobemide, amitriptyline and placebo in depression: a Canadian multicenter study. Psychopharmacology 1992; 106 (suppl.): 98-101
58. Moll E, Neumann N, Schmid-Burg W. Safety and efficacy during long-term treatment with moclobemide. Neuropharmacolgy 1994; 17 (suppl. 1): 74-87
59. O'Brien S, McKeon P, O'Regan M. The efficacy and tolerability of combined antidepressant treatment in different depressive subgroups. Brit J Psychiatry 1993; 162: 363-368
60. Rabkin JG, Quitkin FM, McGrath P, Harrison W, Tricamo E. Adverse reactions to monoamine oxidase inhibitors. Part II. Treatment correlates and clinical management. J Clin Psychopharmacol 1985; 5: 2-9
61. Remick RA, Froese C, Keller FD. Common side effects associated with monoamine oxidase inhibitors. Prog in Neuro-Psychopharmacol & Biol Psychiat 1989; 13: 497-504
62. Harris B, Young J, Hughes B. Comparative effects of seven antidepressant regimes on appetite, weight and carbohydrate preference. Brit J Psychiatry 1986; 148: 590-592
63. Solyom L, Solyom C, Ledwidge B. Trazodone treatment of bulimia nervosa. J Clin Psychopharmacol 1989; 9: 287-290
64. Coxhead N, Silverstone T, Cookson J. Carbamazepine versus lithium in the prophylaxis of bipolar affective disorder. Acta Psychiatr Scand 1992; 85: 114-118
65. Himmerich H, Koethe D, Schuld A, Pollmaecher T. Body weight and the plasma levels of leptin and endogenous immune modulators during treatment with carbamazepine or lithium. Pharmacopsychiatry 2003; 36: 235-235
66. Joffe RT, Post RM, Uhde TW. Effect of Carbamazepine on Body Weight in Affectively Ill Patients. J Clin Psychiatry 1986; 47: 313-314
67. Ketter TA, Kalali AH, Weisler RH SPD417 Study Group. A 6-month, multicenter, open-label evaluation of beaded, extended-release carbamazepine capsule monotherapy in bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry 2004; 65: 668-673
68. Privitera MD, Brodie MJ, Mattson RH, Chadwick DW, New W, Wang S. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 2003; 107: 165-175
69. Chadwick D. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicenter randomised double-blind study. Lancet 1999; 354: 13-19
70. Hogan RE, Bertrand ME, Deaton RL, Sommerville KW. Total percentage body weight changes during add-on therapy with tiagabine, carbamazepine and phenytoin. Epilepsy Res 2000; 41: 23-28
71. Mattson RH, Cramer JA, Collins JF. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizure in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264. N Engl J Med 1992; 327: 765-771
72. Biton V. Effect of Antiepileptic Drugs on Bodyweight: Overview and Clinical Implications for the Treatment of Epilepsy. CNS Drugs 2003; 17: 781-791
73. Baulac M, Cavalcanti D, Semah F, Arzimanoglou A Portal JJ. Gabapentin add-on therapy with adaptable dosages in 610 patients with partial epilepsy: an open, observational study. The French Gabapentin Collaborative Group. Seizure 1998; 7: 55-62
74. Frye MA Ketter TA, Kimbrell TA, Dunn RT, Speer AM, Osuch EA, Luckenbaugh DA Cora-Locatelli GL, Gabriele S, Post RM. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000; 20: 607-614
75. Mathew NT, Rapoport A, Saper J, Magnus L, Klapper J, Ramadan N, Stacey B, Tepper S. Efficacy of gabapentin in migraine prophylaxis. Headache 2001; 41: 119-128
76. McLean MJ, Morrell MJ, Willmore LJ, Privitera MD, Fought RE, Holmes G, Magnus-Miller L, Bernstein P, Rose-Legatt A. Safety and tolerability of gabapentin as adjunctive therapy in a large, Multicenter Study. Epilepsia 1999; 40: 965-972
77. Wang PW, Santosa C, Schumacher M, Winsberg ME, Strong C, Ketter TA. Gabapentin augmentation therapy in bipolar depression. Bipolar Disorders 2002; 4: 296-301
78. Alvarez-Sabin J, Montaner J, Padro L, Molina CA, Rovira R, Codina A, Quintana M. Gabapentin in late-onset poststroke seizures. Neurology 2002; 59: 1991-1993
79. Mauri MC, Laini V, Scalvini ME, Omboni A, Ferrari V, Clemente A, Salvi V, Cerveri G. Gabapentin and the prophylaxis of bipolar disorders in patients intolerant to lithium. Clinical Drug Investigation 2001; 21: 169-174
80. Asconape J, Collins T. Weight gain associated with the use of gabapentin. Epilepsia 1995; 36 (suppl. 4): S72-S72
81. Detoledo JC, Toledo C, Decerce J, Ramsay RE. Changes in body weight with chronic, high-dose gabapentin therapy. Ther Drug Monit 1997; 19: 394-396
82. Garofalo EA Hartman T, Hayes A, Koto EM, Lamoreaux LK. Weight changes during a gabapentin (Neurontin) 26-week monotherapy trial (945-82). Epilepsia 1996; 37 (suppl. 5): 160
83. Biton V, Mirza W, Vuong A, Hammer AE, Barret PS. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 2001; 56: 172-177
84. Calabrese JR, Suppes T, Bowden CL, Sachs GS, Swann AC, McElroy SL, Kusumakar V, Ascher JA, Earl NL Greene PL, Monaghan ET. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapidcycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry 2000;61:841-850
85. Devinsky O, Vuong A, Hammer AE, Barret PS. Stable weight during lamotrigine therapy: A review of 32 studies. Neurology 2000; 54: 973-975
86. Calabrese JR, Bowden CL, Sachs G, Yatham LN, Behnke K, Mehtonen OP, Montgomery P, Ascher J, Paska W, Earl N, De Veaugh-Geiss J. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003; 64: 1013-1024
87. Vestergaard P, Poulstrup I, Schou M. Prospective studies on a lithium cohort: Tremor, weight gain, diarrhea, psychological complaints. Acta Psychiatr Scand 1988; 78: 434-441
88. Kerry RJ, Liebling LI, Owen G. Weight changes in lithium responders. Acta Psychiatr Scand 1970; 46: 238-243
89. Bowden CL, Grunze H, Mullen J, Brecher M, Paulsson B, Jones M, Vagero M, Svensson K. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry 2005; 66: 111-121
90. Mathew B, Rao JM, Sundari U. Lithium-induced changes in the body mass. Acta Psychiatr Scand 1989; 80: 538-540
91. Dean C, Mosier M, Penry K. Dose-response study of vigabatrin as addon therapy in patients with uncontrolled complex partial seizures. Epilepsia 1999; 40: 74-82
92. de Feo MR, Mercarelli O, Marciani MG, Striano S, Tata MR, D'Alessandro P, Cerone G, Ortenzi A Onofri M. Vigabatrin monotherapy in newly diagnosed partial epilepsy: An open multicentre Italian pilot study. Med Sci Research 1998; 26: 283-284
93. Tartara A, Manni R, Galimberti CA. Six-year follow-up study on the efficacy and safety of vigabatrin in patients with epilepsy. Acta Neurol Scand 1992; 86: 247-251
94. Guberman A, Bruni J. Long-term open multicentre, add-on trial of vigabatrin in adult resistant partial epilepsy. The Canadian Vigabatrin Study Group. [Clinical Trial. Controlled Clinical Trial. Journal Article. Multicenter Study Seizure 2000; 9 (2): 112-118
95. Bray GA, Hollander P, Klein S, Kushner R, Levy B, Fitchet M, Perry BH. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obesity Research 2003; 11: 722-733
96. Chengapapa KNR, Rathor D, Levine J, Atzert R, Solai L, Parepally H, Levin H, Moffa N, Delaney J, Brar JS. Topiramate as add-on treatment for patients with bipolar mania. Bipolar Disorders 1999; 1: 42-53
97. Marcotte D. Use of topiramate, a new anti-epileptic as a mood stabilizer. J Affective Disord 1998; 50: 245-251
98. McElroy SL, Suppes T, Keck PE, Frye MA, Denicoff KD, Altshuler LL, Brown S, Nolen WA, Kupka RW, Rochussen J, Leverich GS, Post RM. Open-label adjunctive topiramate in the treatment of bipolar disorders. Biol Psychiatry 2000; 47: 1025-1033
99. Shapira NA, Goldsmith TD, McElroy SL. Treatment of binge-eating disorder with topiramate: A clinical case series. J Clin Psychiatry 2000; 61: 368-372
100. Bowden CL, Calabrese JR, McElroy SL et al. A randomized, placebocontrolled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar disorder. Arch Gen Psychiatry 2000; 57: 481-489
101. Tohen M, Ketter TA, Zarate CA, Suppes T, Frye M, Altshuler L, Zajecka J, Schuh LM, Risser RC, Brown E, Baker RW. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry 2003; 160: 1263-1271
102. Corman CL, Leung M, Guberman AH. Weight gain in epileptic patients during treatment with valproic acid: a Retrospective study. Can J Neurol Sci 1997; 24: 240-244
103. Dinesen H, Gram L, Veje A. Weight gain during treatment with valproate. Acta Neurol Scand 1984; 70: 65-69
104. Isojärvi JI, Laatikainen TJ, Pakarinen AJ. Obesity and endocrine disorder in women taking valproate for epilepsy. Ann Neurol 1996; 39: 579-584
105. Allison DB, Mentore JL, Moonseong Heo, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ. Antipsychotic-induced weight gain: A comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686-1696
106. Tollefson GD, Beasley CM, Tran PV. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997; 154: 457-465
107. Zimbroff DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Wozinak PJ, Sebree TB, Wallin BA, Kashkin KB. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 1997; 154: 782-791
108. Kinon BJ, Basson BR, Gilmore JA. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 2001; 62: 92-100
109. Lieberman JA, Tollefson G, Tohen M, Green A, Gur RE, Kahn R, McEvoy J, Perkins D, Sharma T, Zipursky R, Wei H, Hamer RM. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: A randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 2003; 160: 1396-1404
110. Dufresne RL, Valentino DA, Kass DJ. Thioridazine improves affective symptoms in schizophrenic patients. Psychopharmacol Bull 1993; 29: 249-255
111. Hwang T-J, Lin S-K, Lin H-N. Efficacy and safety of zotepine for the treatment of Taiwanese schizophrenic patients: A double-blind comparison with haloperidol. Journal of the Formosan Medical Association 2001; 100: 811-816
112. Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, Saha A Ali M, Iwamoto T. Aripiprazole in the treatment of schizophrenia: Safety and tolerability in short-term, placebo-controlled trials. Schizophrenia Res 2003; 61: 123-136
113. Petit M, Raniwalla J, Tweed J, Leutenegger E, Dollus S, Kelly F. A comparison of an atypical and typical antipsychotic, zotepine versus haloperidol in patients with acute exacerbation of schizophrenia: a parallel-group double-blind trial. Psychopharmacol Bull 1996; 32: 81-87
114. Tran PV, Tollefson GD, Sanger TM, Lu Y, Berg PH, Beasley CM. Olanzapine versus haloperidol in the treatment of schizoaffective disorder. Acute and long-term therapy. Brit J Psychiatry 1999; 174: 15-22
115. Collins AD, Dundas J. A double-blind trial of amitriptyline/ perphenazine, perphenazine and placebo in chronic withdrawn inert schizophrenics. Brit J Psychiatry 1967; 113: 1425-1429
116. Hoyberg OJ, Fensbo C, Remvig J, Lingjaerde O, Sloth-Nielsen M, Salvesen I. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr Scand 1993; 88: 395-402
117. McCreadie R, Mackie M, Morrison D, Kidd J. Once weekly pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia. Brit J Psychiatry 1982; 140: 280-286
118. Andersen K d'Elia G, Hallberg B, Perris C, Rapp W, Roman G. A controlled trial of pimozide and trifluoperazine in chronic schizophrenic syndromes. Acta Psychiatr Scand 1974; 249 (suppl.): 43-64
119. Denber HC, Turns D. Double blind comparison of thiothixene and trifluoperazine in acute schizophrenia. Psychosomatics 1972; 13: 100-104
120. Gallant DM, Bishop MP. Molindone: a controlled evaluation in chronic schizophrenic patients. Curr Ther Res 1986; 10: 441-447
121. Clark ML, Paredes A, Costiloe JP, Wood F, Barrett A. Loxapine in newly admitted chronic schizophrenic patients. J Clin Pharmacol 1975; 15: 286-294
122. Edwards JG, Alexander JR, Alexander MS, Gordon A, Zutchi T. Controlled trial of sulpiride in chronic schizophrenic patients. British Journal of Psychiatry 1980 Dec; 137: 522-529
123. Leucht S, Wagenpfeil S, Hamann J, Kissling W. Amisulpride is an "atypical" antipsychotic associated with low weight gain. Psychopharmacology 2004; 173 (1-2): 112-115
124. Kane JM, Ingenito G, Ali M. Efficacy of Aripirazole in psychotic disorders: Comparison with haloperidol and placebo. Presented at the 10. biennial winter workshop on schizophrenia February 5-11. Davos, 2000
125. Potkin S, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito G, Marder SR. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003; 60: 681-690
126. Briffa D, Meehan T. Weight changes during clozapine treatment. Aust NZ J Psychiatry 1998; 32: 718-721
127. Juul Povlsen U, Noring U, Fog R, Gerlach J. Tolerability and therapeutic effect of clozapine. A retrospective investigation of 216 patients treated with clozapine for up to 12 years. Acta Psychiatr Scand 1985; 71: 176-185
128. Borison R, Arvanitis LA, Miller BG. USS ICI 204.436, an atypical antipsychotic: efficacy and safety in a multicenter placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol 1996; 16: 158-169
129. Peuskens J, Link CG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 1997; 96: 265-273
130. Small JG, Hirsch SR, Arvantis LA. Quetiapine in patients with schizophrenia: a high- and low-dose double blind comparison with placebo. Arch Gen Psychiatry 1997; 54: 549-557
131. Brecher M, Rak IW, Raniwalla J. The long-term effect of quetiapine monotherapy on weight in patients with schizophrenia. Int J Psychiatry Clin Pract 2000; 4: 287-292
132. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Brit J Psychiatry 1995; 166: 712-726
133. Kelly DL, Conley RR, Love RC. Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months. J Child Adolesc Psychopharmacol 1998; 8: 151-159
134. Ganguli R. Weight gain associated with antipsychotic drugs. J Clin Psychiatry 1999; 60 (suppl. 21): 20-24
135. Daniel DG, Zimbroff DL, Potkin SG. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropsychopharmacology 1999; 20: 491-505
136. Keck PE, Buffenstein A, Ferguson J. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology 1998; 140: 173-184
137. Keck PE, Versiani M, Potkin S, Weste SA, Ciller E, Ice K. Ziprasidone in the treatment of acute bipolar mania: A three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry 2003; 160: 741-748
138. Tandon R, Harrigan E, Zom SH. Ziprasidone: a novel antipsychotic with unique pharmacology and therapeutic potential. J Serotonin Res 1997; 4: 159-177
139. Cooper SJ, Butler A, Tweed J. Zotepine in the prevention of recurrence: a randomised, double-blind, placebo-controlled study for chronic schizophrenia. Psychopharmacology 1998; 150: 237-243
140. Wetterling T, Muessigbrodt H. Body weight increase a side effect of zotepine. Nervenarzt 1996; 67: 256-261
141. Berken GH, Weinstein DO, Stem WC. Weight gain - a side effect of tricyclic antidepressants. J Affective Disord 1984; 7: 133-138
142. Garland EJ, Remick RA. Weight Gain with Antidepressants and Lithium. J Clin Psychopharmacol 1988; 8: 323-330
143. Davis R, Wilde MI. Mirtazapine. A review of its pharmacology and therapeutic potential in the management of major depression. CNS Drugs 1996; 5: 389-402
144. Goodnick PJ, Kremer CM, Wingard P. Weight change during mirtazapine therapy. Primary Psychiatry 1999; 6: 103-108
145. Amdisen A. Drug produced obesity: experiences with chlorpromazine, perphenazine, and clopenthixol. Dan Med Bull 1964; 11: 182-189
146. Robinson RG, McHugh PR, Folstein MF. Measurement of appetite disturbances in psychiatric disorders. J Psychiatr Res 1975; 12: 59-68
147. Johnson DA, Breen M. Weight changes with depot neuroleptic maintenance therapy. J Clin Psychiatry 1979; 59: 525-528
148. Arvanitis LA, Miller BG. Multiple fixed doses of Seroquel (Quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. Biol Psychiatry 1997; 42: 233-246
149. Jalenques Y, Tauveron Y, Albuisson E, Eudy V, Fleury-Duhamel N, Coudert AJ. Weight gain as a predictor of long term clozapine efficacy. CNS Drugs 1996; 12: 16-25
150. Bai YM, Lin CC, Chen JY, Lin CY. Weight gain among patients on clozapine. Psychiatric Services 1999; 50: 704-705
151. Leadbetter R, Shutty M, Pavalonis D, Vieweg V, Higgins P, Downs M. Clozapine-induced weight gain: prevalence and clinical relevance. Am J Psychiatry 1992; 149: 68-72
152. Schmauss M, Wolff R, Erfurth A, Ruther E. Tolerability of long term clozapine treatment. Psychopharmacology 1989; 99: 105-108
153. Umbricht DS, Pollack S, Kane JM. Clozapine and weight gain. J Clin Psychiatry 1994; 55 (suppl. B): 157-160
154. Caffey EM. Experiences with large-scale interhospital cooperative research in chemotherapy. Am J Psychiatry 1996; 117: 713-719
155. Planansky K, Heilizer F. Weight changes in relation to the characteristic patients on chlorpromazine. J Clin Exp Psychol 1959; 20: 53-57
156. Wetterling T, Mussigbrodt HE. Weight gain: a side effect of atypical neuroleptics. J Clin Psychopharmacol 1999; 19: 316-321
157. Kalucy R. Drug induced weight gain. Drugs 1980; 19: 268-278
158. Peselow ED, Dunner DL, Fieve RR, Lautin A. Lithium carbonate and weight gain. J Affect disord 1980; 2: 303-310
159. Kraus T, Zimermann U, Schuld A Haack M, Hinze-Selch D, Pollmacher T. Zur Pathophysiologie der Gewichtsregulation im Rahmen der Therapie mit Psychopharmaka. Fortschr Neurol Psychiat 2001; 69: 116-137
160. Vendsborg PB, Prytz S. Glucose tolerance and serum lipids in man after long-term lithium administration. Acta Psychiatr Scand 1976; 53: 64-69
161. Vestergaard P, Amdisen A, Schou M. Clinically significant side-effects of lithium treatment. A survey of 237 patients in long-term treatment. Acta Psychiatr Scand 1980; 62: 193-200
162. Baptista T, Contreras Q, Alastre T, Burguera JL, de Burguera M, de Baptista E, Weiss S, Hernàndez L. Lithium and body weight gain. Pharmacopsychiat 1995; 28: 35-44
163. Spitz MC, Deasy DN. Conversion of valproate monotherapy in nonretared adults with primary generalized tonic-clonic seizure. J Epilepsy 1991; 4: 33-38
164. Verotti A, Basciani F, Morresi S, de Martino M, Morgese G, Chiarelli F. Serum leptin changes in epileptic patients who gain weight after therapy with valproic acid. Neurology 1999; 53: 230-232
165. Fernstrom MH. Depression, antidepressants, and body weight change. Ann N YAcad Sci 1989; 575: 31-39
166. Harris B, Young J, Hughes B. Appetite and Weight Change in Patients Presenting with Depressive Illness. J Affect Disord 1984; 6: 331-339
167. Stanton JM. Weight gain associated with neuroleptic medication: a review. Schizophr Bull 1995; 21: 463-472
168. Wetterling T. Weight gain from atypical neuroleptics - an underreported adverse effect? Fortschr Neurol Psychiat 2000; 68: 546-556
169. Fiji H, Meinders AE. Bodyweight change as an adverse effect of drug treatment. Drug Safety 1996; 14: 329-342
170. Tecott LH, Sun LM, Akana SF, Strack AM, Lowenstein DH, Dallman MF, Julius D. Eating disorder and epilepsy in mice lacking 5-HT 2c serotonin receptors. Nature 1995; 374: 542-546
171. Ketter TA, Theodore WH. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology 1999; 53 (suppl. 2): 53-67
172. Mclntyre RS, Macini DA, Basile VS. Mechanisms of antipsychotic-induced weight gain. J Clin Psychiatry 2001; 62 (suppl. 23): 23-29
173. Meltzer HY. Role of serotonin in the action of atypical antipsychotic drugs. Clin Neurosci 1995; 3: 64-75
174. Basile VS, Massellis M, McIntyre RS, Meltzer HY, Lieberman JA, Kennedy JL. Genetic Dissection of Atypical Antipsychotic-Induced Weight Gain: Novel Preliminary Data on the Pharmacogenic Puzzle. J Clin Psychiatry 2001; 62 (suppl. 23): 45-66
175. Platman SR, Fieve RR. Lithium carbonate and plasma Cortisol response in affective disorders. Arch Gen Psychiatry 1968; 18: 591-594
176. Baptista T. Body weight gain induced by antipsychotic drugs: mechanisms and management. Acta Psychiatr Scand 1999; 100: 3-16
177. Baptista T, Lacruz A, de Mendoza Guillén S, Silvera R, Angeles F, Mendoza MT, Hernàndez L. Body weight gain after administration of antipsychotic drugs: Correlation with leptin, insulin and reproductive hormones. Pharmacopsychiat 2000; 33: 81-88
178. Esel E, Ozsoy S, Tutus A, Sofuoglu S, Kartalci S, Bayram F, Kokbudak Z, Kula M. Effects of antidepressant treatment and of gender on serum leptin levels in patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 565-570
179. Atmaca M, Kuloglu M, Tezcan E, Ustundag B. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry 2003; 64: 598-604
180. Velde CD van der, Gordon MW. Manic-depressive illness, diabetes mellitus, and lithium carbonate. Arch Gen Psychiatry 1996; 21: 478-485
181. Cassidy F, Ahearn E, Carroll BJ. Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Am J Psychiatry 1999; 156: 1417-1420
182. Kraus T, Haack M, Schuld A Hinze-Selch D, Koethe D, Pollmacher T. Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine. Pharmacopsychiatry 2002; 35: 220-225
183. George TP, Sernyak MJ, Ziedonis DM. Effects of clozapine on smoking in chronic schizophrenic outpatients. J Clin Psychiatry 1995; 56: 344-346
184. Demers R, Heninger G. Pretibial edema and sodium retention during lithium carbonate treatment. JAMA 1970; 214: 1845-1848
185. Kimura T, Matsui K, Sato T. Mechanisms of carbamazepine induced antidiuresis: evidence for release of antidiuretic hormone and impaired excretion of a water load. J Clin Endocrinol Metab 1974; 38: 356-362
186. Chue P, Cheung R. The impact of weight gain associated with atypical antipsychotic use in schizophrenia. Acta Neuropsychiatrica 2004; 16: 113-123
187. Deshmukh R, Franco K. Managing weight gain as a side effect of antidepressant therapy. Clev Clin J Med 2003; 70: 614-618
188. Kupfer DJ, Coble PA, Rubinstein D. Changes in weight during treatment for depression. Psychosom Med 1979; 41: 535-544
189. Paykel ES, Mueller PS, De La Vergne PM. Amitriptyline, weight gain and carbohydrate craving: a side effect. Brit J Psychiatry 1973; 123: 501-507
190. Ferguson JM, Mendels J, Manowitz N. Dothiepin versus doxepin in major depression: Results of a multicenter, placebo-controlled trial. J Clin Psychiat 1994; 55: 258-263
191. Lodge GJ, Freeman HL. Cloyoxamine and doxepin in major depressive disorder: a double-blind controlled trial. Br J Psychiatry 1986; 148: 718-721
192. Remick RA, Keller FD, Gibson RE, Carter D. A comparison between fluoxetine and doxepin in depressed patients. Curr Ther Res Clin E 1989; 46: 842-848
193. Fernstrom MH, Krowinski RL Kupfer DJ. Chronic imipramine treatment and weight gain. Psychiatry Research 1986; 17: 269-273
194. Nemeroff CB, Evans DL, Gyulai L, Sachs GS, Bowden CL, Gergel IP, Oakes R, Pitts CD. Double-Blind, Placebo-Controlled Comparison of Imipramine and Paroxetine in the Treatment of Bipolar Depression. Am J Psychiatry 2001; 158: 906-912
195. Fava M, Dunner D, Greist J, Preskom S, Trivedi MH, Zajecka J, Cohen M. Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: An open-label trial. J Clin Psychiat 2001; 62: 413-420
196. Montgomery SA Safety of mirtazapine: a review. Int Clin Psychopharmocol 1995; 10(suppl. 4): 37-45
197. Coxhead N, Silverstone T, Cookson J. Carbamazepine versus lithium in the prophylaxis of bipolar affective disorder. Acta Psychiatr Scand 1992; 85: 114-118
198. Hogan RE, Garnett WR, Thadani VM. Tolerability and effects on quality of life of twice-daily extended-release carbamazepine in adults with seizure disorders: An open-label, 12- to 36-month continuation study. Clin Ther 2003; 25: 2586-2596
199. Schou M, Baastrup PC, Grof P. Pharmacological and clinical problems of lithium prophylaxis. Brit J Psychiatry 1970; 116: 615-619
200. Italian Study Group Vigabatrin. Single-blind, placebo-controlled multicenter trial of vigabatrin in the treatment of epilepsy. Ital J of Neurol Sci 1992; 13: 741-747
201. Heinrich K, Lehmann E. Low dose neuroleptanxiolysis in anxiety states. Prog Neuro-Psychopharmacol 87 Biol-Psychiat 1992; 16: 135-143
202. Magnus RV. Fluspirilen und Fluphenazin-Dekanoat bei schizophrenen Patienten. Vergleichende Studie. MMW - Münchener Medizinische Wochenschrift 1980; 122: 1758-1760
203. Schmidt LG. Utilization and safety of fluspirilene in nonpsychotic outpatients. Pharmacopsychiat 1989; 22: 188-191
204. Falloon I, Watt D, Sheperd M. Pimozide and fluphenazine decanoate in continuation therapy. Psychol Med 1978; 8: 59-70
205. Johnson DA, Breen M. Weight changes with depot neuroleptic maintenance therapy. J Clin Psychiatry 1997; 59: 525-528
206. Marriott P, Pansa M, Hiep A. Depot fluphenazine maintenance treatment and associated weight changes. Compr Psychiatry 1981; 22: 320-325
207. Beasley CM, Hamilton SH, Crawford AM, Dellva MA, Tollefson CD, Tran PV, Blin O, Beuzen J-N. Olanzapin versus haloperidol: acute phase results of the international double-blind olanzapine trial. Euro Neuropsychopharmacol 1997; 7: 125-137
208. Bustillo JR, Buchanan RW, Irish D. Differential effect of clozapine on weight: a controlled study. Am J Psychiatry 1996; 153: 817-819
209. Claus A, Bollen J, De Cuyper H, Eneman M, Malfroid M, Peuskens J, Heylen S. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand 1992; 85: 295-305
210. Keks N, McGrath J, Lambert T, Catts S, Vaddadi K, Burrows G, Varghese F, George T, Hustig H, Burnett P et al. The Australian multicentre double-blind comparative study of remoxipride and thioridazine in schizophrenia. Acta Psychiatr Scand 1994; 90: 358-365
211. McCreadie RG, Todd N, Livingston M, Eccleston D, Watt JA, Herrington RN, Tait D, Crocket G, Mitchell MJ, Huitfeldt B. A double-blind comparative study of remoxipride and thioridazine in the acute phase of schizophrenia. Acta Psychiatr Scand 1990; 358 (suppl.): 136-137
212. Loo H, Poirier-Littre MF, Theron M, Rein W, Fleurot O. Amisulpiride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Brit J Psychiatry 1997; 170: 18-22
213. Bondolfi G, Dufour H, Patris M, Billeter U, Eap CB, Baumann P. Risperidone versus clozapine in the treatment-resistant chronic schizophrenia: a randomized double blind study. Am J Psychiatry 1998; 155: 499-504
214. Tohen M, Jacobs TG, Grundy SL, McElroy SL, Banov MC, Janicak PG, Sanger T, Risser R, Zhang F, Toma V, Francis J, Tollefson GD, Breier A. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2000; 57: 841-849
215. Osser DN, Najarian DM, Dufresne RL. Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry 1999; 60: 767-770
216. Soholm B, Lublin H. Long-term effectiveness of risperidone and olanzapine in resistant or intolerant schizophrenic patients. A mirror study. Acta Psychiatr Scand May 2003; 107: 344-350
217. Yatham LN, Binder C, Riccardelli R, Leblanc J, Connolly M, Kusumakar V. On behalf of the RIS-CAN 25 Study Group. Risperidone in acute and continuation treatment of mania. Int Clin Psychopharmacol 2003; 18: 227-235
218. Baptista T, Alastre T, Contreras Q, Martinez JL, De Baptista EA, Paez X, Hernandez L. Effects of the antipsychotic drug sulpiride on reproductive hormones in healthy men: Relationship with body weight regulation. Pharmacopsychiat 1997; 30: 250-255
219. Baptista T, Molina MG, Martinez JL, de Quijada M, Calanche de Cuesta I, Acosta A, Paez X, Martinez JM, Hernandez L. Effects of the antipsychotic drug sulpiride on reproductive hormones in healthy premenopausal women: relationship with body weight regulation. Pharmacopsychiat 1997; 30: 256-262